TXA 302

Drug Profile

TXA 302

Alternative Names: TXA-302

Latest Information Update: 03 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TarixCVM
  • Class Peptides
  • Mechanism of Action Haematopoietic cell growth factor stimulants; Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Metabolic disorders; Stroke

Most Recent Events

  • 03 Aug 2016 Preclinical trials in Cardiovascular disorders in USA (SC)
  • 03 Aug 2016 Preclinical trials in Metabolic disorders in USA (SC)
  • 03 Aug 2016 Preclinical trials in Stroke in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top